The combination of RAF265 and BEZ 235 (a PI3K inhibitor) significantly inhibited the growth of xenograft tumors with KRAS and RET mutations, suggesting that blocking the ERK and PI3K signaling pathways can effectively inhibit tumor progression in differentiated and medullary thyroid cancer [287]. Here, KRAS is linked to neoplasm.